Literature DB >> 16941580

Reference data representative of normal findings at three-dimensional power Doppler ultrasound examination of the cervix from 17 to 41 gestational weeks.

L Rovas1, P Sladkevicius, E Strobel, L Valentin.   

Abstract

OBJECTIVES: To develop normal reference ranges for cervical volume and vascular indices using three-dimensional (3D) power Doppler ultrasonography from 17 to 41 gestational weeks.
METHODS: This was a cross-sectional study of 352 nulliparous and 291 parous women who delivered at term and underwent transvaginal 3D power Doppler ultrasound examination of the cervix once at 17 to 41 weeks' gestation. We examined approximately 25 women in each gestational week. Cervical volume, vascularization index (VI), flow index (FI) and vascularization flow index (VFI) were calculated.
RESULTS: There was no change in cervical volume between 17 and 40 weeks' gestation. At 41 weeks cervical volume was slightly smaller than it was at 17-40 weeks (P=0.03 for nulliparous women and P=0.08 for parous women). The cervical volume was larger in parous than it was in nulliparous women (median 38 cm3 vs. 32 cm3 at 17-40 weeks, P<0.0001; median 31 cm3 vs. 22 cm3 at 41 gestational weeks, P=0.288). FI did not differ between nulliparous and parous women and remained unchanged between 17 and 41 weeks' gestation (median 30.6, range 21.2-55.2). VI and VFI did not change consistently from 17 to 41 weeks, but the values were higher in parous than they were in nulliparous women at 17-30 weeks (median VI 5.3% vs. 3.1%, P<0.0001; median VFI 1.6 vs. 0.9, P<0.0001). At 31-41 gestational weeks the median VI for all women irrespective of parity was 4.9% and the median VFI was 1.4.
CONCLUSION: Reference values for cervical volume and blood flow indices as assessed by 3D power Doppler ultrasonography have been established for the second half of pregnancy. These lay the basis for studies of pathological conditions. Copyright (c) 2006 ISUOG.

Entities:  

Mesh:

Year:  2006        PMID: 16941580     DOI: 10.1002/uog.2857

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  6 in total

1.  System-level biomechanical approach for the evaluation of term and preterm pregnancy maintenance.

Authors:  Hussam Mahmoud; Amy Wagoner Johnson; Edward K Chien; Michael J Poellmann; Barbara McFarlin
Journal:  J Biomech Eng       Date:  2013-02       Impact factor: 2.097

2.  Is maternal parity an independent risk factor for birth defects?

Authors:  Hao T Duong; Adrienne T Hoyt; Suzan L Carmichael; Suzanne M Gilboa; Mark A Canfield; Amy Case; Melanie L McNeese; Dorothy Kim Waller
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2012-02-28

Review 3.  Maternal reproductive history and the risk of congenital heart defects in offspring: a systematic review and meta-analysis.

Authors:  Yu Feng; Song Wang; Liyan Zhao; Di Yu; Liang Hu; Xuming Mo
Journal:  Pediatr Cardiol       Date:  2014-12-12       Impact factor: 1.655

4.  Comparison of cervical parameters by three-dimensional ultrasound according to parity and previous delivery mode.

Authors:  Yun Sung Jo; Dong Gyu Jang; Narinay Kim; Sa Jin Kim; Guisera Lee
Journal:  Int J Med Sci       Date:  2011-10-21       Impact factor: 3.738

5.  Maternal parity and the risk of congenital heart defects in offspring: a dose-response meta-analysis of epidemiological observational studies.

Authors:  Yu Feng; Di Yu; Tao Chen; Jin Liu; Xing Tong; Lei Yang; Min Da; Shutong Shen; Changfeng Fan; Song Wang; Xuming Mo
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

6.  Maternal risk associated with the VACTERL association: A case-control study.

Authors:  Romy van de Putte; Hermien E K de Walle; Kirsten J M van Hooijdonk; Ivo de Blaauw; Carlo L M Marcelis; Arno van Heijst; Jacques C Giltay; Kirsten Y Renkema; Paul M A Broens; Erwin Brosens; Cornelius E J Sloots; Jorieke E H Bergman; Nel Roeleveld; Iris A L M van Rooij
Journal:  Birth Defects Res       Date:  2020-07-22       Impact factor: 2.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.